Novo Nordisk, Eli Lilly, Pfizer, Roche, Amgen, and Viking Therapeutics are developing new weight-loss drugs
Novo Nordisk, Eli Lilly, Pfizer, Roche, Amgen, and Viking Therapeutics are developing new weight-loss drugs. Novo Nordisk is working on CagriSema and amycretin, while Eli Lilly has Foundayo, retatrutide, and EloraTZP. Roche's enicepatide showed 15.5% weight loss in mid-stage trials, with late-stage tests planned for 2027. Amgen's MariTide is in late-stage trials for obesity and related conditions.
How this was made
The 30-second read
Why it matters
New efficacy data for Roche's enicepatide and Amgen's MariTide extension provide fresh material that could shift investor sentiment toward biotech obesity plays.
Market read
The fresh trial data and pipeline updates add material information for investors tracking the obesity‑treatment sector, potentially prompting re‑rating of the highlighted companies.
What to watch
Potential safety concerns or competitive pressure from other pipeline drugs could temper enthusiasm.
Background
The article surveys new obesity‑treatment candidates across six major pharma companies, highlighting recent trial outcomes and pipeline status.
Ticker impact
Novo Nordisk is developing new weight‑loss candidates CagriSema and amycretin, adding to its pipeline after Wegovy success.
likely upward pressure as investors price in potential new blockbuster drugs
No trial data yet, but pipeline growth is viewed favorably by the market.
Eli Lilly is advancing three weight‑loss programs (Foundayo, retatrutide, EloraTZP) in late‑stage testing.
moderate upside as investors anticipate future approvals
Multiple candidates increase the chance of a successful launch, but no data released yet.
Pfizer is working on a code‑named obesity candidate PF‑3944, still early in development.
minimal short‑term movement; long‑term upside if data materializes
No trial results disclosed; merely a pipeline mention.
Amgen is testing MariTide in six late‑stage obesity and related‑condition trials, with recent extension data showing sustained weight loss.
moderate upside as investors value the durability of weight‑loss effect
Extension study data are new but limited; still early in the development timeline.
Market effects
Obesity‑treatment sector gains visibility; peers may see increased investor interest.
European biotech (Roche) and US biotech (Amgen, Novo Nordisk) both benefit from fresh data.
Weight‑loss drug pipeline progress is a global theme influencing biotech valuations.
Counterpoint
Investors may remain cautious until pivotal Phase 3 data, as many candidates still face regulatory hurdles.
Key entities
- CompanyNovo Nordisk
Danish pharma developing CagriSema and amycretin.
- CompanyEli Lilly
US pharma with three obesity candidates.
- CompanyPfizer
US pharma with code‑named candidate PF‑3944.
- CompanyRoche
Swiss biotech reporting 15.5% average weight loss in mid‑stage trial.
- CompanyAmgen
US biotech testing MariTide in multiple late‑stage studies.
